Ongoing digital monitoring could be about to solve one of modern medicine’s most frustrating access problems. Life-extending cancer immunotherapies exist and there are numerous patients who could benefit from such therapies, but a mandatory hospital stay requirement currently makes access to immunotherapy nigh impossible for rural and underserved patients.
However, a growing body of evidence now suggests that continuous remote monitoring could remove the need for hospital stays post immunotherapy.
CAR-T cell therapies and related immunotherapies have reshaped what is possible for patients with certain blood cancers, producing remission rates that were unthinkable a generation ago. Thirteen of these treatments now carry FDA approval across two therapy categories. Getting them to patients, however, remains a serious problem. Anyone receiving them must spend several days in hospital afterward, because of a dangerous inflammatory complication the treatment can trigger, cytokine release syndrome, making it difficult for many cancer patients to receive the treatment they need.
When immune cells activate during treatment, they can release a surge of inflammatory proteins that overwhelm the body’s systems. Symptoms range from fever and discomfort to organ failure at the extreme end. Clinical data puts incidence anywhere between 42% and 100% of recipients, with life-threatening severity occurring in a substantial subset of patients. Managing that risk demands continuous in-hospital observation, a model built around resources that major academic centers have but most community hospitals do not.
Wearable devices paired with AI-driven analysis offer a way out of that constraint. Rather than recording vital signs at fixed points during the day, sensor-equipped wearables push a constant physiological data feed into machine learning systems.
Those systems are built to catch the warning signals that appear before a serious reaction develops by issuing alerts to clinicians when significant changes are detected. Armed with this data, physicians can decide whether the patient needs to come in or can safely remain at home.
Beyond the safety application, the data these systems generate does something periodic measurement cannot. A reading captured at a single moment tells clinicians where a patient is at one point in time. Data gathered continuously tells them where that patient is heading and how quickly, offering a richer tapestry of data.
Standard trial designs frequently miss the rapid immune activity unfolding in the first hours after treatment, simply because check-ins are too infrequent to capture it. Continuous monitoring of patients could close that gap.
Researchers stand to gain considerably more from that richer record. Machine learning analysis applied across large patient datasets could help identify the physiological signatures that distinguish effective immune response from dangerous overactivation. Spotting that difference earlier and with greater consistency could drive better decisions around dosing and administration in next-generation therapy development.
For patients in rural or underserved areas who cannot easily reach a facility capable of delivering and monitoring immunotherapy, mandatory hospital stays effectively bar them from receiving immunotherapy. Continuous digital monitoring removes that barrier, and in doing so, brings a category of life-extending therapies within the reach of patients who have had no realistic access to them.
As more patients access these transformational treatments, many more firms would be encouraged to join the ranks of entities like Calidi Biotherapeutics Inc. (NYSE American: CLDI) seeking to develop novel immune-based therapies to address the needs of the large patient population.
About TinyGems
TinyGems is a specialized communications platform with a focus on innovative small-cap and mid-cap companies with bright futures and huge potential. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TinyGems is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, TinyGems brings its clients unparalleled recognition and brand awareness. TinyGems is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.TinyGems.com
Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer
TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com
TinyGems is powered by IBN
